Search

Search Constraints

You searched for: Author/Creator Lalic, Nebojsa

Search Results

1. Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel. (February 2021)

2. Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial. Issue 6 (29th April 2021)

3. Distribution of normal and pathological OGTTs among pregnant population and non-pregnant women with PCOS – the cross-sectional study. Issue 37 (17th September 2021)

4. Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27, 585 people with type 1 and insulin-treated type 2 diabetes. (August 2017)

5. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. (29th August 2020)

6. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. (May 2019)

7. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. (December 2016)

8. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. (29th August 2020)

9. Mineralocorticoid receptor antagonists, a class beyond spironolactone — Focus on the special pharmacologic properties of eplerenone. (1st December 2015)

10. Mineralocorticoid receptor antagonists, a class beyond spironolactone — Focus on the special pharmacologic properties of eplerenone. (1st December 2015)